Caption Management, LLC Insmed Inc Call Options Transaction History

Caption Management, LLC

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $920,776 - $1.07 Million	35,800 New	35,800 $971,000
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $486,570 - $659,785	24,500 Added 27.84%	112,500 $2.84 Million
Q2 2023 Aug 14, 2023	SELL	$16.44 - $21.1 $328,800 - $422,000	-20,000 Reduced 18.52%	88,000 $1.86 Million
Q1 2023 May 15, 2023	BUY	$16.26 - $21.73 $1.32 Million - $1.76 Million	81,000 Added 300.0%	108,000 $1.84 Million
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $458,460 - $625,050	27,000 New	27,000 $539,000

Q1 2022 May 13, 2022	BUY	$20.42 - $28.13 $612,600 - $843,900	30,000 New	30,000 $705,000
Q4 2021 Feb 11, 2022	SELL	$25.89 - $33.45 $2.33 Million - $3.01 Million	-90,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$22.46 - $29.47 $673,800 - $884,100	30,000 Added 50.0%	90,000 $2.48 Million
Q2 2021 Aug 16, 2021	BUY	$24.17 - $36.01 $563,161 - $839,033	23,300 Added 63.49%	60,000 $1.71 Million
Q3 2020 Nov 16, 2020	BUY	$26.0 - $34.5 $954,200 - $1.27 Million	36,700 New	36,700 $1.18 Million
Q2 2020 Aug 14, 2020	SELL	$14.11 - $29.42 $203,184 - $423,648	-14,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $92,684 - $231,063	6,800 Added 89.47%	14,400 $231,000
Q4 2019 Feb 13, 2020	SELL	$16.12 - $24.98 $441,688 - $684,452	-27,400 Reduced 78.29%	7,600 $181,000
Q3 2019 Nov 14, 2019	BUY	$15.49 - $25.78 $77,450 - $128,900	5,000 Added 16.67%	35,000 $617,000
Q1 2019 May 14, 2019	BUY	$13.91 - $31.15 $417,300 - $934,500	30,000 New	30,000 $872,000

340

141M

2.25M

3.11M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $8.74B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.